According to the announcement of Harbin Pharmaceutical Co., Ltd., the daily closing price increase deviation value of the company's stock exceeded 20% for 2 consecutive trading days on August 10 and 11, 2026, which was an abnormal fluctuation. From August 7 to 11, it went up and down for three consecutive trading days, with a cumulative increase of 32.96%. The turnover rates for the past 3 days were 10.71%, 5.23%, and 26.95%, respectively. The volume of transactions was significant. By the close of trading on August 10, the company's static price-earnings ratio was 52.38 times, significantly higher than the industry's 28.98 times. After self-inspection, the company's fundamentals have not changed, no important information should be disclosed, and investors are reminded to pay attention to transaction risks.

According to the announcement of Harbin Pharmaceutical Co., Ltd., the daily closing price increase deviation value of the company's stock exceeded 20% for 2 consecutive trading days on August 10 and 11, 2026, which was an abnormal fluctuation. From August 7 to 11, it went up and down for three consecutive trading days, with a cumulative increase of 32.96%. The turnover rates for the past 3 days were 10.71%, 5.23%, and 26.95%, respectively. The volume of transactions was significant. By the close of trading on August 10, the company's static price-earnings ratio was 52.38 times, significantly higher than the industry's 28.98 times. After self-inspection, the company's fundamentals have not changed, no important information should be disclosed, and investors are reminded to pay attention to transaction risks.